Abstract 832P
Background
Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.
Methods
1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.
Results
The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.
Conclusions
The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
202P - eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors
Presenter: Andrew Truong
Session: Poster session 09
203P - An innovative evidence-based laboratory medicine (EBLM) test to help doctors in multi-cancer early detection (MCED)
Presenter: Jose D Santotoribio
Session: Poster session 09
204P - Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey
Presenter: Rodrigo Paredes
Session: Poster session 09
205P - Detection and diagnosis of lung cancer by electronic nose analysis of exhaled breath: A multi-center prospective observational study
Presenter: Alessandra Buma
Session: Poster session 09
206P - Unveiling the link: How metabolic syndrome drives endometrial cancer progression
Presenter: Lirong Zhai
Session: Poster session 09
Resources:
Abstract
207P - Associations of diabetic background retinopathy and ER+ breast cancer risk: A Mendelian randomization study
Presenter: Shu Wang
Session: Poster session 09
208P - Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?
Presenter: Daniele Fanale
Session: Poster session 09
209P - A novel method for early evaluation of drug-specific predictive biomarker
Presenter: Gal Dinstag
Session: Poster session 09
210P - Therapeutic implications of phosphoproteomics in molecular cancer diagnostics
Presenter: Annika Schneider
Session: Poster session 09
211P - GynePDX: A new platform of preclinical models for endometrial and ovarian cancers
Presenter: Melek Denizli
Session: Poster session 09